137 related articles for article (PubMed ID: 36366811)
41. Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea.
Joung JY; Lim J; Oh CM; Jung KW; Cho H; Kim SH; Seo HK; Park WS; Chung J; Lee KH; Won YJ
Cancer Res Treat; 2017 Jul; 49(3):607-615. PubMed ID: 27658388
[TBL] [Abstract][Full Text] [Related]
42. Uterine carcinosarcomas: From pathology to practice.
Toboni MD; Crane EK; Brown J; Shushkevich A; Chiang S; Slomovitz BM; Levine DA; Dowdy SC; Klopp A; Powell MA; Thaker PH
Gynecol Oncol; 2021 Jul; 162(1):235-241. PubMed ID: 34030871
[TBL] [Abstract][Full Text] [Related]
43. Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma.
Cory L; Brensinger C; Burger RA; Giuntoli RL; Morgan MA; Latif N; Lin LL; Ko EM
Gynecol Oncol Rep; 2022 Feb; 39():100930. PubMed ID: 35111895
[TBL] [Abstract][Full Text] [Related]
44. Uterine and Ovarian Carcinosarcomas: Do They Behave Similarly?
Ureyen I; Karalok A; Cirik DA; Tasci T; Gokce ZK; Duzguner IB; Tulunay G; Turan T
J Obstet Gynaecol Can; 2017 Jul; 39(7):559-563. PubMed ID: 28625283
[TBL] [Abstract][Full Text] [Related]
45. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
46. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant therapy and prognosis in uterine carcinosarcoma.
Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.
Gibbs J; Mei S; Economos K; Lee YC; Kanis MJ
Am J Obstet Gynecol; 2019 Jul; 221(1):53.e1-53.e6. PubMed ID: 30849352
[TBL] [Abstract][Full Text] [Related]
49. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016.
Jung KW; Won YJ; Kong HJ; Lee ES
Cancer Res Treat; 2019 Apr; 51(2):417-430. PubMed ID: 30913865
[TBL] [Abstract][Full Text] [Related]
50. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014.
Jung KW; Won YJ; Oh CM; Kong HJ; Lee DH; Lee KH;
Cancer Res Treat; 2017 Apr; 49(2):292-305. PubMed ID: 28279062
[TBL] [Abstract][Full Text] [Related]
51. Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry.
Lee EG; Jung SY; Lim MC; Lim J; Kang HS; Lee S; Han JH; Jo H; Won YJ; Lee ES
Cancer Res Treat; 2020 Jul; 52(3):739-746. PubMed ID: 32054149
[TBL] [Abstract][Full Text] [Related]
52. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).
Cha J; Kim YS; Park W; Kim HJ; Kim JY; Kim JH; Kim J; Yoon WS; Kim JW; Kim YB
J Gynecol Oncol; 2016 Nov; 27(6):e58. PubMed ID: 27550404
[TBL] [Abstract][Full Text] [Related]
53. Identification of distinct molecular subtypes of uterine carcinosarcoma.
An Y; Wang H; Jie J; Tang Y; Zhang W; Ji S; Guo X
Oncotarget; 2017 Feb; 8(9):15878-15886. PubMed ID: 28178664
[TBL] [Abstract][Full Text] [Related]
54. Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis.
Wong AT; Lee YC; Schwartz D; Lee A; Shao M; Han P; Choi K; Schreiber D
Int J Gynecol Cancer; 2017 Jul; 27(6):1171-1177. PubMed ID: 28574930
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
[TBL] [Abstract][Full Text] [Related]
56. Uterine carcinosarcomas: incidence and trends in management and survival.
Arrastia CD; Fruchter RG; Clark M; Maiman M; Remy JC; Macasaet M; Gates EJ; Di Maio T; Marzec T
Gynecol Oncol; 1997 Apr; 65(1):158-63. PubMed ID: 9103406
[TBL] [Abstract][Full Text] [Related]
57. Nationwide surveillance in uterine cancer: survival analysis and the importance of birth cohort: 30-year population-based registry in Taiwan.
Huang CY; Chen CA; Chen YL; Chiang CJ; Hsu TH; Lin MC; Lai MS; Chen CJ; You SL; Cheng WF
PLoS One; 2012; 7(12):e51372. PubMed ID: 23251510
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors impacting survival in early stage uterine carcinosarcoma.
Kurnit KC; Previs RA; Soliman PT; Westin SN; Klopp AH; Fellman BM; Lu KH; Ramondetta LM; Fleming ND
Gynecol Oncol; 2019 Jan; 152(1):31-37. PubMed ID: 30414738
[TBL] [Abstract][Full Text] [Related]
59. Epidemiology and prediction model of patients with carcinosarcoma in the United States.
Chen M; He X; Yang Q; Zhang J; Peng J; Wang D; Tong K; Huang W
Front Public Health; 2022; 10():1038211. PubMed ID: 36518582
[TBL] [Abstract][Full Text] [Related]
60. Trends in the incidence of in situ and invasive cervical cancer by age group and histological type in Korea from 1993 to 2009.
Oh CM; Jung KW; Won YJ; Shin A; Kong HJ; Jun JK; Park SY
PLoS One; 2013; 8(8):e72012. PubMed ID: 23977194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
